A Bayesian Belief Network approach for predicting kernicterus

A lot of research have been conducted using expert systems in the diagnosis of neonatal jaundice but none has been conducted on kernicterus. Kernicterus is a complication of neonatal jaundice in which bilirubin accumulates in the grey matter of the brain, causing an irreversible neurological damage. In this paper, a Bayesian belief network was designed for predicting neonatal jaundice. The BBN model has 15 nodes and had 97% and 94% accuracy in classifying neonatal jaundice and kernicterus respectively.Keywords: Jaundice, Kernicterus, Bayesian Belief Networ

Progeny, June 2013, Vol 29, no.1

This newsletter from The Department of Public Health about perinatal health care and statistics

Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings.

Hyperbilirubinaemia is a ubiquitous transitional morbidity in the vast majority of newborns and a leading cause of hospitalisation in the first week of life worldwide. While timely and effective phototherapy and exchange transfusion are well proven treatments for severe neonatal hyperbilirubinaemia, inappropriate or ineffective treatment of hyperbilirubinaemia, at secondary and tertiary hospitals, still prevails in many poorly-resourced countries accounting for a disproportionately high burden of bilirubin-induced mortality and long-term morbidity. As part of the efforts to curtail the widely reported risks of frequent but avoidable bilirubin-induced neurologic dysfunction (acute bilirubin encephalopathy (ABE) and kernicterus) in low and middle-income countries (LMICs) with significant resource constraints, this article presents a practical framework for the management of late-preterm and term infants (≥ 35 weeks of gestation) with clinically significant hyperbilirubinaemia in these countries particularly where local practice guidelines are lacking. Standard and validated protocols were followed in adapting available evidence-based national guidelines on the management of hyperbilirubinaemia through a collaboration among clinicians and experts on newborn jaundice from different world regions. Tasks and resources required for the comprehensive management of infants with or at risk of severe hyperbilirubinaemia at all levels of healthcare delivery are proposed, covering primary prevention, early detection, diagnosis, monitoring, treatment, and follow-up. Additionally, actionable treatment or referral levels for phototherapy and exchange transfusion are proposed within the context of several confounding factors such as widespread exclusive breastfeeding, infections, blood group incompatibilities and G6PD deficiency, which place infants at high risk of severe hyperbilirubinaemia and bilirubin-induced neurologic dysfunction in LMICs, as well as the limited facilities for clinical investigations and inconsistent functionality of available phototherapy devices. The need to adjust these levels as appropriate depending on the available facilities in each clinical setting and the risk profile of the infant is emphasised with a view to avoiding over-treatment or under-treatment. These recommendations should serve as a valuable reference material for health workers, guide the development of contextually-relevant national guidelines in each LMIC, as well as facilitate effective advocacy and mobilisation of requisite resources for the optimal care of infants with hyperbilirubinaemia at all levels

Successful Pregnancy Outcome In Maternal Crigler Najjar Syndrome Type II.

Estimated incidence of Crigler-Najjar syndrome(CNS) is 1 case per 1,000,000 births(1 million). The overall prevalence of CN syndrome is unknown, with only several hundred people reported to have this disease. It is interestingly very rare to encounter a pregnant adult women with congenital jaundice. Pregnancy in CN type II patients is a diagnostic and a therapeutic challenge because of the high risk of bilirubin encephalopathy with serious neurological damage as life-threatening complications for the fetus. To date 8 pregnancy outcome have been reported from 5 women and we report the6 woman with a successful 9 th pregnancy outcome. We have discussed detail history, presentation and management during pregnancy and care of the new born

RISIKO GANGGUAN PENDENGARAN PADA NEONATUS HIPERBILIRUBINEMIA

ABSTRACT Background. The prevalence of hearing impairment on the Indonesian population according to 2007 WHO data is estimated at 4.2 %, and one of the cause is neonatal hyperbilirubinemia. Early detection of hearing impairment and optimal intervention on the first 6 months can prevent speech and language impairment, lack of academic achievement, disturbance of personal social relationship and emotional in the children. Method. A Cohort research was conducted in 36 neonates in Dr Kariadi Hospital in March 2009-March 2010, 18 in the case group with indirect bilirubin > 12 mg/dl and 18 neonates as control group with indirect bilirubin < 12 mg/dl, both taken with consecutive sampling method. We recorded clinical, laboratory, and tymphanometry data, OAE and BERA results at first and after three months. Statistical analysis were done using Chi-square analysis, Mc Nemar analysis, and T-test. Results. Hearing impairment on the first BERA examination was 9 cases (25%) and 3 cases (8.3%) on the second BERA examination, however it did not differed significantly (p>0,05). On the first BERA examination, the mean indirect bilirubin concentration with hearing impairment of 14,18+6,289 mg/dl was not significantly different (p>0,05) from neonate without hearing impairment of 11,29+2,995 mg/dl. The Relative Risk (RR) was 2 (p>0,05; 95% CI 0,6-6,8), but statistically it was not significant. Conclusion. The incidence of hearing impairment on neonatal with hyperbilirubinemia is 25%. Indirect bilirubin of > 12 mg/dL is not proved to be the risk factor of hearing impairment in neonatal with hyperbilirubinemia. Keywords:BERA, hearing impairment, neonatal hyperbilirubinemia, OAE

Brainstem auditory evoked responses in an equine patient population. Part II: foals.

BackgroundReports of the use of brainstem auditory evoked response (BAER) as a diagnostic modality in foals have been limited.Hypothesis/objectivesTo describe BAER findings and associated causes of hearing loss in foals.AnimalsStudy group 18 foals (15 neonatal, 3 nonneonatal), control group (5 neonatal foals).MethodsRetrospective. BAER records from the Clinical Neurophysiology Laboratory were reviewed from the years of 1982 to 2013. Peak latencies, amplitudes, and interpeak intervals were measured when visible. Clinical data were extracted from the medical records. Foals were grouped under disease categories. Descriptive statistics were performed.ResultsTen neonatal foals had complete absence of BAER bilaterally and 5 had findings within reference range. Abnormalities were associated with common neonatal disorders such as sepsis, neonatal encephalopathy, neonatal isoerythrolysis, and prematurity. BAER loss also was observed in foals with specific coat color patterns such as completely or mostly white with blue irides or lavender with pale yellow irides. An American Miniature foal with marked facial deformation also lacked BAER bilaterally. One nonneonatal foal with an intracranial abscess had no detectable BAER peaks bilaterally, and 2 older foals, 1 with presumed equine protozoal myeloencephalitis and the other with progressive scoliosis and ataxia, had BAER within normal limits.Conclusions and clinical importanceIn neonatal foals, BAER deficits commonly are complete and bilateral, and associated with common neonatal disorders and certain coat and eye color patterns. Sepsis, hypoxia, bilirubin toxicity, and prematurity should be investigated as potential causes of auditory loss in neonatal foals

The effects of Bilirubin and Bilirubin-di-taurate on ischemia reperfusion injruy in a rat model of kidney transplantation

Background: Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in the conversion of heme into biliverdin, carbon monoxide (CO) and free iron. Biliverdin is then subsequently reduced to bilirubin by the enzyme bilverdin reductase. In the past decades a lot of effort was conducted to investigate the beneficial effects of HO-1 and its end products biliverdin/bilirubin and CO. Due to intensive research, solid organ transplantation can nowadays be seen as clinical routine. However ischemia reperfusion injury (IR), acute rejection episodes and the occurrence of chronic rejection remain main problems. The severity of IRI can be seen as a prognostic factor for early graft function, immunogenecity of grafts as well as for long term graft survival. The goal of our experiments was to investigate the potential beneficial effects of bilirubin and biliverdin on ischemia reperfusion in a kidney transplantation model of the rat. Methods: Two different sets of experiments were performed: First, kidneys of Lewis rats were exposed to 60 minutes of warm ischemia by clamping the renal artery followed by a 24h reperfusion period. This model was used to find the optimal dosing regimen of bilirubin/biliverdin before the more clinical relevant model of kidney transplantation in the rat was performed. We found that three doses of 10mg/Kg bilirubin were the most effective dose regimen to protect kidneys from ischemia reperfusion injury. In the second set of experiments, kidney transplantation was performed in Lewis rats. Kidneys were harvested and stored in 4C cold UW-solution for 18h. Subsequently the kidneys were transplanted isotopically into the recipient rat. Time of warm ischemia was kept in all experiments constantly at 60 minutes. After 24h of reperfusion tissue samples and serum were harvested for further analyses. Results: Systemic treatment of bilirubin led to a significant amelioration of organ function after ischemia reperfusion injury as assessed by measuring serum creatinine levels and BUN levels after 24h of reperfusion. In addition treated animals showed increased eGFR and a better cell integrity as histomorphological analyses could demonstrate. Conclusion: Systemic treatment with bilirubin and bilverdin has beneficial effects on graft function after ischemia rerperfusion injury

Changes in globus pallidus with (pre)term kernicterus

OBJECTIVE: We report serial magnetic resonance (MR) and sonographic behavior of globus pallidus in 5 preterm and 3 term infants with kernicterus and describe the clinical context in very low birth weight preterm infants. On the basis of this information, we suggest means of diagnosis and prevention. METHODS: Charts and MR and ultrasound images of 5 preterm infants and 3 term infants with suspected bilirubin-associated brain damage were reviewed. Included were preterm infants with severe hearing loss, quadriplegic hypertonia, and abnormal hypersignal of globus pallidus on T2-weighted MR imaging (MRI). In 1 infant who died on day 150, the diagnosis was confirmed during the neonatal period. The others were picked up as outpatients and scanned at 12 or 22 months' corrected age. Three instances of term kernicterus were included for comparison of serial MRI in the neonatal period and early infancy: they were caused by glucose-6-phosphate dehydrogenase deficiency, urosepsis, and dehydration plus fructose 1-6 biphosphatase deficiency. RESULTS: Five preterm infants of 25 to 29 weeks' gestational age presented with total serum bilirubin (TSB) levels below exchange transfusion thresholds commonly advised. Mixed acidosis was present in 3 infants around the TSB peak. The bilirubin/albumin molar ratio was >0.5 in all, in the absence of displacing drugs. All failed to pass bedside hearing screen tests and had severe hearing loss on auditory brain response testing. Symmetrical homogeneous hyperechogenicity of globus pallidus was the alerting feature in 1 infant. Globus pallidus was hyperintense on T1-weighted MR images in this child. The other infants presented with severe developmental delay as a result of dyskinetic quadriplegia and hearing loss. Globus pallidus was normal on T1- but hyperintense on T2-weighted MR images at 12

Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.

BACKGROUND: Rhesus (Rh) disease and extreme hyperbilirubinemia (EHB) result in neonatal mortality and long-term neurodevelopmental impairment, yet there are no estimates of their burden. METHODS: Systematic reviews and meta-analyses were undertaken of national prevalence, mortality, and kernicterus due to Rh disease and EHB. We applied a compartmental model to estimate neonatal survivors and impairment cases for 2010. RESULTS: Twenty-four million (18% of 134 million live births ≥ 32 wk gestational age from 184 countries; uncertainty range: 23-26 million) were at risk for neonatal hyperbilirubinemia-related adverse outcomes. Of these, 480,700 (0.36%) had either Rh disease (373,300; uncertainty range: 271,800-477,500) or developed EHB from other causes (107,400; uncertainty range: 57,000-131,000), with a 24% risk for death (114,100; uncertainty range: 59,700-172,000), 13% for kernicterus (75,400), and 11% for stillbirths. Three-quarters of mortality occurred in sub-Saharan Africa and South Asia. Kernicterus with Rh disease ranged from 38, 28, 28, and 25/100,000 live births for Eastern Europe/Central Asian, sub-Saharan African, South Asian, and Latin American regions, respectively. More than 83% of survivors with kernicterus had one or more impairments. CONCLUSION: Failure to prevent Rh sensitization and manage neonatal hyperbilirubinemia results in 114,100 avoidable neonatal deaths and many children grow up with disabilities. Proven solutions remain underused, especially in low-income countries